Back

Mechanisms of cardiovascular impact of SGLT2 inhibitors.

27 August 2018 (11:45 - 12:07)
Organised by:
Congress Presentation Part of: How do SGLT2 inhibitors and incretin-based therapy exert their effects on cardiovascular disease? Diabetes and the Heart ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Bart Staels

Lille Cedex (France)

3 More presentations in this session

Presentation thumbnail
Epigenetic signatures and cardiovascular risk in diabetes.
Professor F. Cosentino (Stockholm, SE)
Presentation thumbnail
Use of incretin-based therapies.
Professor L. Ryden (Stockholm, SE)
Slides Video
Presentation thumbnail
SGLT2 inhibitors and alteration of substrate metabolism.
Professor E. Ferrannini (Pisa, IT)
Slides Video

Access the full session

Session thumbnail
How do SGLT2 inhibitors and incretin-based therapy exert their effects on cardiovascular disease?

The Event

Event poster

ESC Congress 2018

27 August 2018 11:45 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular benefits of SGLT2i in type 2 diabetes without heart failure: a subgroup analysis
30 August 2025
thumbnail
Congress Presentation
Mechanistic insights of SGLT2 inhibitors effectiveness
30 August 2025
thumbnail
Webinar
The role of imaging in the diabetic heart
6 October 2022
thumbnail
Congress Session
Risk prediction and treatment: bring your crystal ball?
19 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources